{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:11:41Z","timestamp":1790413901152,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:00:00Z","timestamp":1502150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007072","name":"Onyx Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The management of Waldenstr\u00f6m macroglobulinaemia (<jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content>) relies predominantly on small trials, one of which has demonstrated activity of dexamethasone, rituximab and cyclophosphamide (<jats:styled-content style=\"fixed-case\">DRC<\/jats:styled-content>) in the frontline setting. We report on the efficacy of <jats:styled-content style=\"fixed-case\">DRC<\/jats:styled-content>, focusing on relapsed\/refractory (R\/R) patients. Ibrutinib, a recently approved agent in <jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content> demonstrated limited activity in patients with <jats:italic><jats:styled-content style=\"fixed-case\">MYD<\/jats:styled-content>88<\/jats:italic><jats:styled-content style=\"fixed-case\"><jats:sup>WT<\/jats:sup><\/jats:styled-content> genotype. Herein, we additionally report on the activity of <jats:styled-content style=\"fixed-case\">DRC<\/jats:styled-content> based on the <jats:italic><jats:styled-content style=\"fixed-case\">MYD<\/jats:styled-content>88<\/jats:italic><jats:sup>L265P<\/jats:sup> mutation status. Of 100 <jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content> patients evaluated between January 2007 and December 2014 who received <jats:styled-content style=\"fixed-case\">DRC<\/jats:styled-content>, 50 had R\/R <jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content>. The overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>) was 87%. The median progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and time\u2010to\u2010next\u2010therapy (<jats:styled-content style=\"fixed-case\">TTNT<\/jats:styled-content>) were 32 (95% confidence interval [<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>]: 15\u201351) and 50 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 35\u201360) months, respectively. In the previously untreated cohort (<jats:italic>n<\/jats:italic>\u00a0=\u00a050), the <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> was 96%, and the median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">TTNT<\/jats:styled-content> were 34\u00a0months (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 23\u2013not reached [<jats:styled-content style=\"fixed-case\">NR<\/jats:styled-content>]) and <jats:styled-content style=\"fixed-case\">NR<\/jats:styled-content> (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 37\u2013<jats:styled-content style=\"fixed-case\">NR<\/jats:styled-content>), respectively. Twenty\u2010five (86%) of 29 genotyped patients harbored <jats:italic><jats:styled-content style=\"fixed-case\">MYD<\/jats:styled-content>88<\/jats:italic><jats:sup>L265P<\/jats:sup>. The response rates and outcomes were independent of <jats:italic><jats:styled-content style=\"fixed-case\">MYD<\/jats:styled-content>88<\/jats:italic> mutation status. Grade \u22653 adverse effects included neutropenia (20%), thrombocytopenia (7%) and infections (3%). Similar to the frontline setting, <jats:styled-content style=\"fixed-case\">DRC<\/jats:styled-content> is an effective and well\u2010tolerated salvage regimen for <jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content>. In contrast to ibrutinib, <jats:styled-content style=\"fixed-case\">DRC<\/jats:styled-content> offers a less expensive, fixed\u2010duration option, with preliminary data suggesting efficacy independent of the patients\u2019 <jats:italic><jats:styled-content style=\"fixed-case\">MYD<\/jats:styled-content>88<\/jats:italic> status.<\/jats:p>","DOI":"10.1111\/bjh.14826","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T12:02:37Z","timestamp":1502193757000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Dexamethasone, rituximab and cyclophosphamide for relapsed\u00a0and\/or refractory and treatment\u2010na\u00efve patients with Waldenstrom macroglobulinemia"],"prefix":"10.1111","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1358","authenticated-orcid":false,"given":"Amanda","family":"Shreders","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Jacksonville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Jacksonville FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[{"name":"Division of Hematopathology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,8]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Drug Information Handbook\u00ae","author":"Lexicom","year":"2016"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0178-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716654102"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1222380"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8659"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.8522","article-title":"Phase I study of ABT\u2010199 (GDC\u20100199) in patients with relapsed\/refractory (R\/R) non\u2010Hodgkin lymphoma (NHL): responses observed in diffuse large B\u2010cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses","volume":"32","author":"Davids M.","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.9926"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30632-5"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001714043"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07892.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3237"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21788"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-525808"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-754523"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.03.001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0391-7"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5763"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647420"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50038"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.1530"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.018"},{"key":"e_1_2_7_26_1","volume-title":"Drug Information Handbook\u00ae","author":"Lexicomp\u00ae","year":"2016"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50082"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12102"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177329"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566273"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550905"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1506192"},{"key":"e_1_2_7_38_1","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.V126.23.1486.1486","article-title":"The clonal architecture of CXCR4 mutations in Waldenstrom's macroglobulinemia shows highly variable subclonal distribution, and multiple mutations within individual patients indicative of targeted genomic instability","volume":"126","author":"Xu L.","year":"2015","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1111%2Fbjh.14826","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:27:26Z","timestamp":1696296446000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/bjh.14826"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14826","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,8]]},"assertion":[{"value":"2017-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}